Gilford Securities Reiterates Buy Rating on Summer Infant Following Mixed 2Q13 Results

In a report published Friday, Gilford Securities analyst Robert D. Straus reiterated a Buy rating on

. In the report, Gilford Securities noted, “Summer Infant, Inc. designs, markets and distributes juvenile health and wellness products through retail partners in the United States, the United Kingdom, and Canada. Management is now focused on improving its margin structure – and will do so at the expense of sales. The company's retail program to sales relationship remains a critical unknown.” Summer Infant closed on Thursday at $3.29.